Treatment with natural human interferon alpha of a CML-patient with antibodies to recombinant interferon alpha-2b.
A patient with Philadelphia-chromosome positive chronic myelogenous leukemia developed interferon antibodies on treatment with recombinant interferon alpha-2b. Clinically this event corresponded with progressive disease. No cross-reactivity of antibodies with human leukocyte interferon was found by Western blot. Treatment was switched to human leukocyte interferon with an obvious clinical effect: WBC was reduced and platelet count stabilized, but the effect was transient and no hematologic remission was achieved. Human leukocyte interferon may be an alternative in CML-patients with neutralizing antibodies to recombinant interferon alpha.
Freund
M
M
Department Hematology/Oncology, Hannover Medical School.
von Wussow
P
P
Knüver-Hopf
J
J
Mohr
H
H
Pohl
U
U
Exeriede
G
G
Link
H
H
Wilke
H J
HJ
Poliwoda
H
H
D000917:Antibody Formation; D002066:Busulfan / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003429:Cross Reactions; D004351:Drug Resistance; D006801:Humans; D007370:Interferon Type I / Q000276:immunology* / Q000627:therapeutic use*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000276:immunology* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012074:Remission Induction
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D002066:Busulfan